Caxton Associates LP Has $92,000 Stock Holdings in Alector, Inc. (NASDAQ:ALEC)

Caxton Associates LP increased its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 41.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,282 shares of the company’s stock after acquiring an additional 5,933 shares during the period. Caxton Associates LP’s holdings in Alector were worth $92,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Federated Hermes Inc. boosted its holdings in Alector by 4.1% during the second quarter. Federated Hermes Inc. now owns 68,538 shares of the company’s stock valued at $311,000 after purchasing an additional 2,709 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Alector by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 112,920 shares of the company’s stock worth $513,000 after buying an additional 3,790 shares during the period. ProShare Advisors LLC boosted its stake in Alector by 24.1% in the 1st quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock valued at $119,000 after buying an additional 3,827 shares in the last quarter. American International Group Inc. grew its position in Alector by 13.0% in the first quarter. American International Group Inc. now owns 35,655 shares of the company’s stock valued at $215,000 after acquiring an additional 4,105 shares during the period. Finally, Rafferty Asset Management LLC grew its position in Alector by 2.3% in the fourth quarter. Rafferty Asset Management LLC now owns 190,911 shares of the company’s stock valued at $1,523,000 after acquiring an additional 4,287 shares during the period. Institutional investors own 85.83% of the company’s stock.

Alector Stock Performance

Shares of ALEC opened at $4.92 on Friday. The company has a market cap of $474.21 million, a price-to-earnings ratio of -3.57 and a beta of 0.68. The stock has a fifty day moving average price of $5.43 and a two-hundred day moving average price of $5.32. Alector, Inc. has a 52-week low of $3.66 and a 52-week high of $8.90.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. The business had revenue of $15.08 million during the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. During the same period in the previous year, the business posted $0.02 earnings per share. As a group, research analysts predict that Alector, Inc. will post -1.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ALEC shares. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a research note on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Alector in a research report on Thursday, June 20th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $17.75.

Insiders Place Their Bets

In other news, CFO Marc Grasso sold 7,297 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $35,609.36. Following the transaction, the chief financial officer now directly owns 130,740 shares in the company, valued at $638,011.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Arnon Rosenthal sold 26,499 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the transaction, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at approximately $9,509,880.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Marc Grasso sold 7,297 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $35,609.36. Following the completion of the transaction, the chief financial officer now owns 130,740 shares in the company, valued at $638,011.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 58,222 shares of company stock valued at $286,013. Insiders own 9.10% of the company’s stock.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.